Healthcare Services Group, Inc.
Healthcare Services Group, Inc. (HCSG) Stock Competitors & Peer Comparison
See (HCSG) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCSG | $19.89 | -1.24% | 1.4B | 23.96 | $0.83 | N/A |
| HCA | $509.87 | -2.92% | 114B | 17.98 | $28.35 | +0.57% |
| THC | $211.64 | -3.49% | 18.6B | 13.67 | $15.48 | N/A |
| FMS | $23.16 | +0.65% | 13.3B | 12.00 | $1.93 | +3.38% |
| UHS | $193.46 | -0.01% | 12.3B | 8.38 | $23.09 | +0.41% |
| ENSG | $210.38 | +0.44% | 12.2B | 36.09 | $5.83 | +0.12% |
| SOLV | $68.67 | +2.28% | 11.9B | 7.73 | $8.88 | N/A |
| EHC | $101.57 | +0.14% | 10.2B | 18.11 | $5.61 | +0.71% |
| DVA | $149.98 | +1.19% | 10B | 15.76 | $9.52 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
HCSG vs HCA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, HCA has a market cap of 114B. Regarding current trading prices, HCSG is priced at $19.89, while HCA trades at $509.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas HCA's P/E ratio is 17.98. In terms of profitability, HCSG's ROE is +0.12%, compared to HCA's ROE of -1.41%. Regarding short-term risk, HCSG is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check HCA's competition here
HCSG vs THC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, THC has a market cap of 18.6B. Regarding current trading prices, HCSG is priced at $19.89, while THC trades at $211.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas THC's P/E ratio is 13.67. In terms of profitability, HCSG's ROE is +0.12%, compared to THC's ROE of +0.35%. Regarding short-term risk, HCSG is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check THC's competition here
HCSG vs FMS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, FMS has a market cap of 13.3B. Regarding current trading prices, HCSG is priced at $19.89, while FMS trades at $23.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas FMS's P/E ratio is 12.00. In terms of profitability, HCSG's ROE is +0.12%, compared to FMS's ROE of +0.07%. Regarding short-term risk, HCSG is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check FMS's competition here
HCSG vs UHS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, UHS has a market cap of 12.3B. Regarding current trading prices, HCSG is priced at $19.89, while UHS trades at $193.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas UHS's P/E ratio is 8.38. In terms of profitability, HCSG's ROE is +0.12%, compared to UHS's ROE of +0.21%. Regarding short-term risk, HCSG is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check UHS's competition here
HCSG vs ENSG Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ENSG has a market cap of 12.2B. Regarding current trading prices, HCSG is priced at $19.89, while ENSG trades at $210.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ENSG's P/E ratio is 36.09. In terms of profitability, HCSG's ROE is +0.12%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, HCSG is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check ENSG's competition here
HCSG vs SOLV Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SOLV has a market cap of 11.9B. Regarding current trading prices, HCSG is priced at $19.89, while SOLV trades at $68.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SOLV's P/E ratio is 7.73. In terms of profitability, HCSG's ROE is +0.12%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, HCSG is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check SOLV's competition here
HCSG vs EHC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, EHC has a market cap of 10.2B. Regarding current trading prices, HCSG is priced at $19.89, while EHC trades at $101.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas EHC's P/E ratio is 18.11. In terms of profitability, HCSG's ROE is +0.12%, compared to EHC's ROE of +0.24%. Regarding short-term risk, HCSG is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check EHC's competition here
HCSG vs DVA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, DVA has a market cap of 10B. Regarding current trading prices, HCSG is priced at $19.89, while DVA trades at $149.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas DVA's P/E ratio is 15.76. In terms of profitability, HCSG's ROE is +0.12%, compared to DVA's ROE of -1.61%. Regarding short-term risk, HCSG is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check DVA's competition here
HCSG vs OSH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, HCSG is priced at $19.89, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas OSH's P/E ratio is -17.65. In terms of profitability, HCSG's ROE is +0.12%, compared to OSH's ROE of +4.64%. Regarding short-term risk, HCSG is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check OSH's competition here
HCSG vs CHE Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CHE has a market cap of 5.6B. Regarding current trading prices, HCSG is priced at $19.89, while CHE trades at $399.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CHE's P/E ratio is 21.78. In terms of profitability, HCSG's ROE is +0.12%, compared to CHE's ROE of +0.24%. Regarding short-term risk, HCSG is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check CHE's competition here
HCSG vs LHCG Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, HCSG is priced at $19.89, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas LHCG's P/E ratio is 82.83. In terms of profitability, HCSG's ROE is +0.12%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, HCSG is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check LHCG's competition here
HCSG vs MMED Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, MMED has a market cap of 4.7B. Regarding current trading prices, HCSG is priced at $19.89, while MMED trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas MMED's P/E ratio is -17.90. In terms of profitability, HCSG's ROE is +0.12%, compared to MMED's ROE of -0.07%. Regarding short-term risk, HCSG is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check MMED's competition here
HCSG vs OPCH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, OPCH has a market cap of 4.7B. Regarding current trading prices, HCSG is priced at $19.89, while OPCH trades at $29.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas OPCH's P/E ratio is 23.43. In terms of profitability, HCSG's ROE is +0.12%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, HCSG is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check OPCH's competition here
HCSG vs BKD Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, BKD has a market cap of 3.5B. Regarding current trading prices, HCSG is priced at $19.89, while BKD trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas BKD's P/E ratio is -12.76. In terms of profitability, HCSG's ROE is +0.12%, compared to BKD's ROE of -5.24%. Regarding short-term risk, HCSG is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check BKD's competition here
HCSG vs AMED Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, HCSG is priced at $19.89, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AMED's P/E ratio is 39.30. In terms of profitability, HCSG's ROE is +0.12%, compared to AMED's ROE of +0.13%. Regarding short-term risk, HCSG is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check AMED's competition here
HCSG vs LFST Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, LFST has a market cap of 2.6B. Regarding current trading prices, HCSG is priced at $19.89, while LFST trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas LFST's P/E ratio is 329.00. In terms of profitability, HCSG's ROE is +0.12%, compared to LFST's ROE of +0.01%. Regarding short-term risk, HCSG is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check LFST's competition here
HCSG vs NHC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, HCSG is priced at $19.89, while NHC trades at $162.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas NHC's P/E ratio is 21.18. In terms of profitability, HCSG's ROE is +0.12%, compared to NHC's ROE of +0.12%. Regarding short-term risk, HCSG is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check NHC's competition here
HCSG vs ACHC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ACHC has a market cap of 2.2B. Regarding current trading prices, HCSG is priced at $19.89, while ACHC trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ACHC's P/E ratio is -1.95. In terms of profitability, HCSG's ROE is +0.12%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, HCSG is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check ACHC's competition here
HCSG vs SEM Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, HCSG is priced at $19.89, while SEM trades at $16.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SEM's P/E ratio is 14.01. In terms of profitability, HCSG's ROE is +0.12%, compared to SEM's ROE of +0.09%. Regarding short-term risk, HCSG is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check SEM's competition here
HCSG vs ADUS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ADUS has a market cap of 1.9B. Regarding current trading prices, HCSG is priced at $19.89, while ADUS trades at $101.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ADUS's P/E ratio is 19.45. In terms of profitability, HCSG's ROE is +0.12%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, HCSG is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check ADUS's competition here
HCSG vs AMEH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, HCSG is priced at $19.89, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AMEH's P/E ratio is 39.25. In terms of profitability, HCSG's ROE is +0.12%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, HCSG is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AMEH's competition here
HCSG vs MD Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, HCSG is priced at $19.89, while MD trades at $19.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas MD's P/E ratio is 10.11. In terms of profitability, HCSG's ROE is +0.12%, compared to MD's ROE of +0.20%. Regarding short-term risk, HCSG is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check MD's competition here
HCSG vs SGRY Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SGRY has a market cap of 1.6B. Regarding current trading prices, HCSG is priced at $19.89, while SGRY trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SGRY's P/E ratio is -20.74. In terms of profitability, HCSG's ROE is +0.12%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, HCSG is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check SGRY's competition here
HCSG vs AVAH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, HCSG is priced at $19.89, while AVAH trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AVAH's P/E ratio is 19.11. In terms of profitability, HCSG's ROE is +0.12%, compared to AVAH's ROE of -1.36%. Regarding short-term risk, HCSG is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AVAH's competition here
HCSG vs ARDT Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, HCSG is priced at $19.89, while ARDT trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ARDT's P/E ratio is 9.69. In terms of profitability, HCSG's ROE is +0.12%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, HCSG is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check ARDT's competition here
HCSG vs ASTH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, HCSG is priced at $19.89, while ASTH trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ASTH's P/E ratio is 53.91. In terms of profitability, HCSG's ROE is +0.12%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, HCSG is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check ASTH's competition here
HCSG vs BKDT Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, HCSG is priced at $19.89, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas BKDT's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, HCSG is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check BKDT's competition here
HCSG vs USPH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, HCSG is priced at $19.89, while USPH trades at $77.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas USPH's P/E ratio is 54.53. In terms of profitability, HCSG's ROE is +0.12%, compared to USPH's ROE of +0.03%. Regarding short-term risk, HCSG is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check USPH's competition here
HCSG vs INNV Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, INNV has a market cap of 1.2B. Regarding current trading prices, HCSG is priced at $19.89, while INNV trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas INNV's P/E ratio is 170.40. In terms of profitability, HCSG's ROE is +0.12%, compared to INNV's ROE of -0.02%. Regarding short-term risk, HCSG is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check INNV's competition here
HCSG vs PNTG Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, HCSG is priced at $19.89, while PNTG trades at $33.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas PNTG's P/E ratio is 39.32. In terms of profitability, HCSG's ROE is +0.12%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, HCSG is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check PNTG's competition here
HCSG vs TALK Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TALK has a market cap of 858.8M. Regarding current trading prices, HCSG is priced at $19.89, while TALK trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TALK's P/E ratio is 128.50. In terms of profitability, HCSG's ROE is +0.12%, compared to TALK's ROE of +0.07%. Regarding short-term risk, HCSG is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check TALK's competition here
HCSG vs FSHCX Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, FSHCX has a market cap of 812.5M. Regarding current trading prices, HCSG is priced at $19.89, while FSHCX trades at $96.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas FSHCX's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to FSHCX's ROE of N/A. Regarding short-term risk, HCSG is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check FSHCX's competition here
HCSG vs AMN Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AMN has a market cap of 712.2M. Regarding current trading prices, HCSG is priced at $19.89, while AMN trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AMN's P/E ratio is -7.43. In terms of profitability, HCSG's ROE is +0.12%, compared to AMN's ROE of -0.15%. Regarding short-term risk, HCSG is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check AMN's competition here
HCSG vs EHAB Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, EHAB has a market cap of 690.6M. Regarding current trading prices, HCSG is priced at $19.89, while EHAB trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas EHAB's P/E ratio is -151.28. In terms of profitability, HCSG's ROE is +0.12%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, HCSG is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check EHAB's competition here
HCSG vs SNDA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SNDA has a market cap of 681M. Regarding current trading prices, HCSG is priced at $19.89, while SNDA trades at $36.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SNDA's P/E ratio is -12.13. In terms of profitability, HCSG's ROE is +0.12%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, HCSG is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check SNDA's competition here
HCSG vs CMPS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CMPS has a market cap of 581.8M. Regarding current trading prices, HCSG is priced at $19.89, while CMPS trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CMPS's P/E ratio is -2.23. In terms of profitability, HCSG's ROE is +0.12%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, HCSG is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CMPS's competition here
HCSG vs MCTA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, HCSG is priced at $19.89, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas MCTA's P/E ratio is 419.36. In terms of profitability, HCSG's ROE is +0.12%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, HCSG is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check MCTA's competition here
HCSG vs CYH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CYH has a market cap of 431.1M. Regarding current trading prices, HCSG is priced at $19.89, while CYH trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CYH's P/E ratio is 0.82. In terms of profitability, HCSG's ROE is +0.12%, compared to CYH's ROE of -0.32%. Regarding short-term risk, HCSG is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CYH's competition here
HCSG vs AUNA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AUNA has a market cap of 427.1M. Regarding current trading prices, HCSG is priced at $19.89, while AUNA trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AUNA's P/E ratio is 5.89. In terms of profitability, HCSG's ROE is +0.12%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, HCSG is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AUNA's competition here
HCSG vs TOI Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TOI has a market cap of 353.2M. Regarding current trading prices, HCSG is priced at $19.89, while TOI trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TOI's P/E ratio is -4.72. In terms of profitability, HCSG's ROE is +0.12%, compared to TOI's ROE of +7.60%. Regarding short-term risk, HCSG is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check TOI's competition here
HCSG vs AONC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, HCSG is priced at $19.89, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AONC's P/E ratio is -13.48. In terms of profitability, HCSG's ROE is +0.12%, compared to AONC's ROE of -0.02%. Regarding short-term risk, HCSG is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check AONC's competition here
HCSG vs CCRN Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CCRN has a market cap of 296.8M. Regarding current trading prices, HCSG is priced at $19.89, while CCRN trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CCRN's P/E ratio is -3.09. In terms of profitability, HCSG's ROE is +0.12%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, HCSG is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CCRN's competition here
HCSG vs AGL Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AGL has a market cap of 255.8M. Regarding current trading prices, HCSG is priced at $19.89, while AGL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AGL's P/E ratio is -0.63. In terms of profitability, HCSG's ROE is +0.12%, compared to AGL's ROE of -1.17%. Regarding short-term risk, HCSG is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AGL's competition here
HCSG vs CSU Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, HCSG is priced at $19.89, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CSU's P/E ratio is 0.67. In terms of profitability, HCSG's ROE is +0.12%, compared to CSU's ROE of -2.10%. Regarding short-term risk, HCSG is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CSU's competition here
HCSG vs AIRS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AIRS has a market cap of 168M. Regarding current trading prices, HCSG is priced at $19.89, while AIRS trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AIRS's P/E ratio is -8.97. In terms of profitability, HCSG's ROE is +0.12%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, HCSG is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AIRS's competition here
HCSG vs JYNT Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, JYNT has a market cap of 128.6M. Regarding current trading prices, HCSG is priced at $19.89, while JYNT trades at $8.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas JYNT's P/E ratio is -423.50. In terms of profitability, HCSG's ROE is +0.12%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, HCSG is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check JYNT's competition here
HCSG vs NAKAW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, HCSG is priced at $19.89, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas NAKAW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to NAKAW's ROE of -0.74%. Regarding short-term risk, HCSG is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check NAKAW's competition here
HCSG vs FVE Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, HCSG is priced at $19.89, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas FVE's P/E ratio is -5.64. In terms of profitability, HCSG's ROE is +0.12%, compared to FVE's ROE of -0.15%. Regarding short-term risk, HCSG is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check FVE's competition here
HCSG vs KDLYW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, HCSG is priced at $19.89, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas KDLYW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, HCSG is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check KDLYW's competition here
HCSG vs DCGO Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, DCGO has a market cap of 76M. Regarding current trading prices, HCSG is priced at $19.89, while DCGO trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas DCGO's P/E ratio is -1.47. In terms of profitability, HCSG's ROE is +0.12%, compared to DCGO's ROE of -5.07%. Regarding short-term risk, HCSG is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check DCGO's competition here
HCSG vs BTMD Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, BTMD has a market cap of 65.1M. Regarding current trading prices, HCSG is priced at $19.89, while BTMD trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas BTMD's P/E ratio is 1.72. In terms of profitability, HCSG's ROE is +0.12%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, HCSG is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check BTMD's competition here
HCSG vs ALR Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, HCSG is priced at $19.89, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ALR's P/E ratio is -1.11. In terms of profitability, HCSG's ROE is +0.12%, compared to ALR's ROE of -0.15%. Regarding short-term risk, HCSG is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check ALR's competition here
HCSG vs IMAC Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, HCSG is priced at $19.89, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas IMAC's P/E ratio is -2.27. In terms of profitability, HCSG's ROE is +0.12%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, HCSG is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check IMAC's competition here
HCSG vs CCEL Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CCEL has a market cap of 24.2M. Regarding current trading prices, HCSG is priced at $19.89, while CCEL trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CCEL's P/E ratio is -10.00. In terms of profitability, HCSG's ROE is +0.12%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, HCSG is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CCEL's competition here
HCSG vs AIH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, HCSG is priced at $19.89, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AIH's P/E ratio is -2.78. In terms of profitability, HCSG's ROE is +0.12%, compared to AIH's ROE of +1.16%. Regarding short-term risk, HCSG is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check AIH's competition here
HCSG vs AMS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, AMS has a market cap of 13.7M. Regarding current trading prices, HCSG is priced at $19.89, while AMS trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas AMS's P/E ratio is -5.97. In terms of profitability, HCSG's ROE is +0.12%, compared to AMS's ROE of -0.09%. Regarding short-term risk, HCSG is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check AMS's competition here
HCSG vs CANO Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, HCSG is priced at $19.89, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CANO's P/E ratio is -0.01. In terms of profitability, HCSG's ROE is +0.12%, compared to CANO's ROE of -1.49%. Regarding short-term risk, HCSG is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check CANO's competition here
HCSG vs FTRP Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, HCSG is priced at $19.89, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas FTRP's P/E ratio is -1.22. In terms of profitability, HCSG's ROE is +0.12%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, HCSG is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check FTRP's competition here
HCSG vs PIII Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, PIII has a market cap of 8.5M. Regarding current trading prices, HCSG is priced at $19.89, while PIII trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas PIII's P/E ratio is -0.05. In terms of profitability, HCSG's ROE is +0.12%, compared to PIII's ROE of -3.18%. Regarding short-term risk, HCSG is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check PIII's competition here
HCSG vs MODV Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, HCSG is priced at $19.89, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas MODV's P/E ratio is -0.03. In terms of profitability, HCSG's ROE is +0.12%, compared to MODV's ROE of +1.84%. Regarding short-term risk, HCSG is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check MODV's competition here
HCSG vs GBNH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, HCSG is priced at $19.89, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas GBNH's P/E ratio is -0.06. In terms of profitability, HCSG's ROE is +0.12%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, HCSG is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check GBNH's competition here
HCSG vs TOIIW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TOIIW has a market cap of 5.4M. Regarding current trading prices, HCSG is priced at $19.89, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TOIIW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, HCSG is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check TOIIW's competition here
HCSG vs RHE-PA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, HCSG is priced at $19.89, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, HCSG's ROE is +0.12%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, HCSG is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check RHE-PA's competition here
HCSG vs RHE Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, HCSG is priced at $19.89, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas RHE's P/E ratio is -1.79. In terms of profitability, HCSG's ROE is +0.12%, compared to RHE's ROE of +0.06%. Regarding short-term risk, HCSG is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check RHE's competition here
HCSG vs ATIP Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, HCSG is priced at $19.89, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas ATIP's P/E ratio is -0.03. In terms of profitability, HCSG's ROE is +0.12%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, HCSG is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check ATIP's competition here
HCSG vs SYRA Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SYRA has a market cap of 1.9M. Regarding current trading prices, HCSG is priced at $19.89, while SYRA trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SYRA's P/E ratio is -1.71. In terms of profitability, HCSG's ROE is +0.12%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, HCSG is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check SYRA's competition here
HCSG vs IMACW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, HCSG is priced at $19.89, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas IMACW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, HCSG is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check IMACW's competition here
HCSG vs TALKW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TALKW has a market cap of 1.1M. Regarding current trading prices, HCSG is priced at $19.89, while TALKW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TALKW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, HCSG is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check TALKW's competition here
HCSG vs MNDR Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, MNDR has a market cap of 747.4K. Regarding current trading prices, HCSG is priced at $19.89, while MNDR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas MNDR's P/E ratio is -0.04. In terms of profitability, HCSG's ROE is +0.12%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, HCSG is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check MNDR's competition here
HCSG vs CCM Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, CCM has a market cap of 531.5K. Regarding current trading prices, HCSG is priced at $19.89, while CCM trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas CCM's P/E ratio is -0.67. In terms of profitability, HCSG's ROE is +0.12%, compared to CCM's ROE of +0.07%. Regarding short-term risk, HCSG is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check CCM's competition here
HCSG vs BACK Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, BACK has a market cap of 212.7K. Regarding current trading prices, HCSG is priced at $19.89, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas BACK's P/E ratio is -0.02. In terms of profitability, HCSG's ROE is +0.12%, compared to BACK's ROE of +1.05%. Regarding short-term risk, HCSG is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check BACK's competition here
HCSG vs NVOS Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, HCSG is priced at $19.89, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas NVOS's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, HCSG is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check NVOS's competition here
HCSG vs NIVFW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, NIVFW has a market cap of 30.7K. Regarding current trading prices, HCSG is priced at $19.89, while NIVFW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas NIVFW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, HCSG is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check NIVFW's competition here
HCSG vs PIIIW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, PIIIW has a market cap of 17.6K. Regarding current trading prices, HCSG is priced at $19.89, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas PIIIW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, HCSG is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check PIIIW's competition here
HCSG vs IONM Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, HCSG is priced at $19.89, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas IONM's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to IONM's ROE of +5.28%. Regarding short-term risk, HCSG is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check IONM's competition here
HCSG vs DVCR Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas DVCR's P/E ratio is 28.34. In terms of profitability, HCSG's ROE is +0.12%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, HCSG is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check DVCR's competition here
HCSG vs TVTY Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TVTY's P/E ratio is 19.06. In terms of profitability, HCSG's ROE is +0.12%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, HCSG is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check TVTY's competition here
HCSG vs NFH Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, NFH has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas NFH's P/E ratio is -19.75. In terms of profitability, HCSG's ROE is +0.12%, compared to NFH's ROE of -0.06%. Regarding short-term risk, HCSG is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check NFH's competition here
HCSG vs TLMD Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TLMD's P/E ratio is -1.60. In terms of profitability, HCSG's ROE is +0.12%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, HCSG is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check TLMD's competition here
HCSG vs TLMDW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas TLMDW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, HCSG is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check TLMDW's competition here
HCSG vs HNGR Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas HNGR's P/E ratio is 19.71. In terms of profitability, HCSG's ROE is +0.12%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, HCSG is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check HNGR's competition here
HCSG vs SLHG Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SLHG's P/E ratio is -1.48. In terms of profitability, HCSG's ROE is +0.12%, compared to SLHG's ROE of N/A. Regarding short-term risk, HCSG is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check SLHG's competition here
HCSG vs DCGOW Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas DCGOW's P/E ratio is N/A. In terms of profitability, HCSG's ROE is +0.12%, compared to DCGOW's ROE of -5.07%. Regarding short-term risk, HCSG is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for HCSG.Check DCGOW's competition here
HCSG vs SLHGP Comparison March 2026
HCSG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCSG stands at 1.4B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, HCSG is priced at $19.89, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCSG currently has a P/E ratio of 23.96, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, HCSG's ROE is +0.12%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, HCSG is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for HCSG.Check SLHGP's competition here